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Abstract  
BH3 mimetics are novel targeted drugs with remarkable specificity and potency and enormous 
potential to improve cancer therapy. However, acquired resistance is an emerging problem. We report 
the rapid development of resistance in chronic lymphocytic leukemia cells isolated from patients 
exposed to increasing doses of Navitoclax (ABT-263), a BH3 mimetic. To mimic such rapid 
development of chemoresistance, we have developed simple resistance models to three different BH3 
mimetics, targeting BCL-2 (ABT-199), BCL-XL (A-1331852) or MCL-1 (A-1210477), in relevant 
haematological cancer cell lines. In these models, resistance could be attributed neither to consistent 
changes in expression levels of the anti-apoptotic proteins nor interactions among different pro- and 
anti-apoptotic BCL-2 family members. Using genetic silencing, pharmacological inhibition and 
metabolic supplementation, we report that targeting of glutamine uptake and its downstream 
signalling pathways, namely glutaminolysis, reductive carboxylation, lipogenesis, cholesterogenesis 
and mTOR signalling result in marked sensitisation of the chemoresistant cells to BH3 mimetic-
mediated apoptosis. Furthermore, our findings highlight the possibility of repurposing widely used 
drugs, such as statins, to target intermediary metabolism and improve the efficacy of BH3 mimetic 
therapy.  
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Introduction 
Failure to undergo apoptosis is a cardinal feature of cancer and several targeted therapies, 
such as the small molecule inhibitors targeting specific members of the anti-apoptotic BCL-2 family - 
navitoclax/ ABT-263 (targeting BCL-2, BCL-XL and BCL-w) and venetoclax/ ABT-199 (BCL-2 
specific) - are aimed at facilitating cancer cell clearance by enhanced apoptosis.1-4 Recently, selective 
inhibitors of BCL-XL (A-1331852) and MCL-1 (A-1210477 and S63845) have also been 
synthesised.5-7 Despite their selectivity in targeting distinct anti-apoptotic BCL-2 family members, 
and remarkable potency in inducing rapid and extensive apoptosis in a wide variety of malignancies, 
resistance to BH3 mimetics, in particular venetoclax, is starting to be reported in the clinic. Elevated 
levels of multiple members of the anti-apoptotic BCL-2 family proteins, including BCL-XL and MCL-
1, are often implicated in such chemoresistance.8-13 Although it may be possible to target these 
proteins with a combination of selective BH3 mimetics, the potential toxicities associated with such 
combination therapy may be problematic. 
 Altered metabolism is a promising approach to enhance the efficacy of chemotherapeutic 
agents, as a requirement for intermediary metabolites, such as glucose and glutamine, for the survival 
and proliferation of cancer cells is well documented.1,14-19 This is a promising approach, as drugs 
targeting different stages of intermediary metabolism are already approved or in trials for treating 
different malignancies.20,21 In this study, we report a low level of resistance that developed in chronic 
lymphocytic leukemic (CLL) cells from patients exposed to Navitoclax. To mimic this modest 
resistance, we have developed simple resistance models to different BH3 mimetics and demonstrate 
that downregulating glutamine uptake or metabolism as well as its downstream signalling cascades, 
such as reductive carboxylation, lipogenesis and cholesterogenesis, result in enhanced apoptosis of 
cancer cells resistant to different BH3 mimetics, thus highlighting the possibility that inhibition of key 
regulatory enzymes of these metabolic pathways may enhance sensitivity to BH3 mimetic therapy.  
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Methods 
Reagents and Antibodies 
ABT-263, A-1331852 and A-1210477 were from AbbVie (North Chicago, IL, USA). ABT-199, 
epigallocatechin gallate (EGCG), CB-839, simvastatin, rapamycin and torin-1 from Selleck 
Chemicals (Houston, TX, USA), Gamma-L-glutamyl-p-nitroanilide (GPNA) from Insight 
Biotechnology (Wembley, Middlesex, UK), Azaserine from Cambridge Bioscience (Cambridge, UK), 
aminooxyacetate (AOA), sodium palmitate, filipin, dimethyl α-ketoglutarate, oxaloacetate and citrate 
from Sigma-Aldrich (Gillingham, UK), L-glutamine from Life Technologies (Paisley, UK) and 
GSK2194069, SB204990, atorvastatin, pitavastatin and bafilomycin A1 from Tocris (Abingdon, UK) 
were used. Antibodies against PARP, BCL-2, MCL-1, BAX, BAK and GAPDH from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA), caspase-3, caspase-9, BCL-XL, BCL-w, BIM, PUMA, BAD, 
IDH2, ACL, ACO2, ATG5 and ATG7 from Cell Signalling Technology (MA, USA), BID from Prof. 
J. Borst (The Netherlands Cancer Institute, Amsterdam, The Netherlands), NOXA from Millipore 
(Watford, UK) and SLC1A5, GLS, GFAT, GLUD1, IDH3, FASN and HMGR from Abcam 
(Cambridge, UK) were used.  
Primary CLL cells and Cell lines 
Peripheral blood samples from CLL patients were obtained with patient consent and ethics 
committee approval (06_Q2501_122) from Leicester Haematological Tissue Bank and cultured as 
described.38 CLL samples were obtained from patients enrolled in a Phase 1/2a Study of ABT-263 
(Navitoclax) in patients with relapsed or refractory CLL (NCT00481091). Lymphocytes were purified 
and cultured in RPMI 1640 medium supplemented with 10% foetal bovine serum (FBS) (Life 
Technologies Inc.).  Alternatively, blood from patients was incubated at 37°C in 48-well plates and 
apoptosis assessed as described previously.39,40 Blood samples were collected prior to the first in vivo 
dose of navitoclax or 4 h after dosing during the lead-in-period (L1D1; Day 1 of lead-in-period), or 
day 1 of cycle 1 (C1D1), cycle 3 (C3D1) or cycle 5 (C5D1). Samples were collected 4 h after dosing 
as blood concentrations of ABT-263 were maximal at this time.41 For culture of CLL cells, mouse 
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fibroblast L cells were irradiated with 75 Gray and seeded in 24-well plates (3 x105 cells/ well). CLL 
cells were cultured at 1.5 x 106 cells / well on the L cells and removed when required by gentle 
washing with RPMI before treatment. Mantle cell lymphoma (MAVER-1), chronic myeloid leukemia 
(K562) and multiple myeloma (NCI-H929) cell lines were cultured in RPMI 1640 medium but the 
medium was supplemented with 0.02% 2-mercaptoethanol for culturing H929 cells. Cell lines were 
either from DMSZ (Braunshweig, Germany) or ATCC (Middlesex, UK) and subjected to short 
tandem repeat (STR) profiling to confirm identity.  
Resistance models 
The different resistance models to relevant BH3 mimetics were developed by treating control cells 
(represented as A in all schemes) of MAVER-1, K562 and H929 to the relevant BH3 mimetics, ABT-
199 (10 nM), A-1331852 (10 nM) or A-1210477 (5 µM), respectively. In the first resistance model, 
cells were exposed to their appropriate BH3 mimetic for 24 h followed by 2 weeks (2 w) without drug 
resulting in the cells depicted as B. These cells were further exposed to their appropriate BH3 mimetic 
for a further 24 h followed again by 2 weeks without drug resulting in C. This procedure was repeated 
a further twice resulting in E. In the second resistance model, cells were exposed to their appropriate 
BH3 mimetic for 24 h followed by 8 weeks without drug, resulting in the cells depicted as A4. The 
cells were collected every 2 weeks and labelled as A1, A2 and A3, respectively. In the third resistance 
model, cells were exposed to increasing concentrations of the appropriate BH3 mimetic, every 5 days 
(5 d) resulting in cells depicted as A-a, A-b, A-c and A-d. The fourth model of resistance was made in 
a similar manner, but the 5 d treatment period was split into a 2 d treatment, followed by 3 d without 
drug, resulting in cells depicted as A-i, A-ii, A-iii and A-iv. 
Metabolic deprivation, supplementation and apoptosis measurements 
For glutamine deprivation experiments, cells were washed with PBS and re-suspended in SILAC 
RPMI 1640 Flex Media (Life Technologies Inc.), supplemented with glucose (2 mg/mL) and 10% 
FBS, for 16 h. For supplementation studies, the indicated concentrations of metabolites were added to 
the glutamine free media, immediately before glutamine deprivation. For lipid supplementation 
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studies, sodium palmitate (dissolved in water at 70 °C for a stock concentration of 100 mM and added 
dropwise into fatty acid-free BSA (10%) to produce a final concentration of 10 mM) was 
supplemented in the culture media. The extent of apoptosis in cells following different treatments was 
quantified by FACS following staining of the cells with Annexin V-FITC and propidium iodide to 
measure phosphatidylserine externalisation, as previously described.42  
siRNA knockdowns, immunoprecipitation and western blotting 
Cells were transfected with 10 nM of siRNAs against SLC1A5 (SI00079730), GLS (SI03155019), 
GFAT (SI03246355), GLUD1 (SI02654743), IDH2 (SI02654820), IDH3 (SI00300524), ACO2 
(SI03019037), ACLY (SI02663332), FASN (SI00059752), HMGR (SI00017136), ATG5 
(SI02633946) and ATG7 (SI04344830) from Qiagen Ltd. (Manchester, UK) using Interferin 
(Polyplus Transfection Inc, NY), according to the manufacturer's protocol and processed 72 h after 
transfection. Immunoprecipitation and western blotting were carried out according to standard 
protocols.43  
Statistical Analysis 
One-way ANOVA multiple comparisons and Fishers LSD test P≤0.01 were performed for comparing 
sensitive and resistant cells. For CLL patient samples, one-way repeated measures ANOVA with 
Fishers LSD test P≤0.01 was used and statistics analysed using GraphPad Prism 6 software (La Jolla, 
CA). 
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Results 
Haematological malignancies acquire rapid resistance to BH3 mimetics 
The potential of BH3 mimetic therapy in cancer was first demonstrated in the treatment of 
BCL-2-dependent chronic lymphocytic leukemia (CLL) using navitoclax/ ABT-263. In a phase 1/2 
clinical trial of navitoclax, CLL patients were treated for an initial lead-in-period of 7 days with a low 
dose of navitoclax (100 mg daily) followed by 5-7 treatment cycles, with each cycle lasting 21 days 
during which the patients received 250 mg navitoclax daily. Analysis of the blood samples collected 
from these patients, either prior to the first in vivo dose of navitoclax or 4 h after dosing, during the 
different cycles of therapy revealed marked changes in the ability of navitoclax to induce apoptosis in 
the CLL cells (Fig. 1A). The first in vivo dose of navitoclax on day 1 of the lead-in period (L1D1) 
resulted in a time-dependent induction of apoptosis, as assessed by phosphatidylserine (PS) 
externalisation and ultrastructural changes, in comparison to the CLL cells from the same patients 
prior to treatment (Fig. 1A and Supplemental Fig. 1). A progressive increase in resistance to 
navitoclax was observed in CLL cells in vivo during the different cycles of treatment (Fig. 1A). Since 
these studies were carried out in whole blood, we wished to ascertain whether the decrease in ABT-
263-induced apoptosis in CLL cells could be attributed to chemoresistance.  To test this, CLL cells 
were isolated from these patients at the beginning of each treatment cycle and exposed to increasing 
concentrations of ABT-263. A significant decrease (3-fold difference in the IC50 values between the 
lead-in period and cycle 5) was observed in their ability to undergo ABT-263-induced apoptosis (Fig. 
1B), demonstrating that continued dosing of patients with ABT-263 resulted in a modest, yet 
significant increase in chemoresistance.  
Since chemoresistance is an emerging problem in BH3 mimetic therapy, we wished to extend 
these studies to more selective BH3 mimetics, such as ABT-199, which has replaced navitoclax 
owing to the dose-limiting thrombocytopenia associated with BCL-XL inhibition.3 Moreover, other 
selective BH3 mimetics that target BCL-XL (A-1331852) and MCL-1 (A-1210477 and S63845) have 
been introduced for use in several other malignancies.5-7 Using these BH3 mimetics and relevant 
cancer cell lines, we wished to mimic the rapid resistance observed in CLL patients following 
navitoclax (Fig. 1A and B), in order to identify ways to tackle chemoresistance, as it emerges. For 
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this, we chose the BCL-2-dependent MAVER-1, BCL-XL-dependent K562 and MCL-1-dependent 
H929 cell lines and exposed them to ABT-199, A-1331852 and A-1210477, respectively, to generate 
different resistant models (Fig. 1C and Supplemental Fig. 2). Initial exposure of the relevant cell lines 
to the corresponding BH3 mimetic resulted in a rapid, time-dependent induction of apoptosis as 
assessed by the activation of caspase-9 and -3 as well as the cleavage of the canonical caspase 
substrate, PARP (Supplemental Fig. 2A). Resistance to BH3 mimetics in these cells was generated by 
following the scheme presented (Fig. 1C), when the initially sensitive cells (A) became relatively 
resistant (E), after four exposures (within 8 weeks) to their respective BH3 mimetic (Fig. 1C). 
Similarly, a rapid resistance to the different BH3 mimetics was also observed using the other three 
resistance models (Supplemental Fig. 2B-D). The rapid and modest resistance to the different BH3 
mimetics in these cell lines was comparable to the extent of resistance observed in CLL cells during 
navitoclax therapy (Fig. 1B). 
 
Resistance to BH3 mimetics can be overcome by inhibiting multiple BCL-2 family members 
 Since resistance to BH3 mimetics has often been attributed to elevated expression levels of 
one or more anti-apoptotic BCL-2 family members, we wished to identify whether such changes 
could be responsible for the observed resistance. Comparison of the sensitive (A), intermediate (C) 
and resistant (E) cells from the different cell lines did not reveal any consistent differences in BCL-2 
family expression to explain the resistance (Supplemental Fig. 3). Therefore, we sought to identify 
whether changes in protein-protein interactions among different pro-apoptotic BH3-only members 
and their anti-apoptotic counterparts could explain the resistance to BH3 mimetics. For this, we 
performed immunoprecipitation studies to isolate the anti-apoptotic proteins bound to BIM and 
PUMA, which were abundantly expressed in the three different cell types. However, in the sensitive 
(A) and resistant (E) MAVER-1 cells, immunoprecipitation of BIM and PUMA revealed similar 
binding of BCL-2 and BCL-XL and little or no binding to MCL-1 (Supplemental Fig. 4). Similarly, no 
differences were observed in the binding of BIM and PUMA to BCL-XL and MCL-1 in sensitive and 
resistant K562 or H929 cells (Supplemental Fig. 4).  
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Although the protein expression levels and immunoprecipitation studies did not support an 
involvement of other BCL-2 family proteins in the observed resistance, the resistance to ABT-199 
observed in MAVER-1 cells was completely overcome by a combination of ABT-199 with either A-
1331852 or A-1210477, but not by either A-1331852 or A-1210477 alone, suggesting that the 
resistant cells in addition to BCL-2 also depended on BCL-XL and/or MCL-1 for survival (Fig. 1D). 
Furthermore, a combination of all three BH3 mimetics induced apoptosis in all the resistant cells, 
emphasising the importance of all three anti-apoptotic BCL-2 family members in chemoresistance in 
these cells (Fig. 1D). In K562 and H929 cells, the resistance was overcome by the combination of A-
1331852 and A-1210477, but not ABT-199, thus implicating primary roles for BCL-XL and MCL-1 in 
chemoresistance (Figs. 1E and F). Similar to the MAVER-1 cells, the chemoresistant K562 cells also 
exhibited enhanced apoptosis following a combination of all three BH3 mimetics (Fig. 1E), 
suggesting that some contribution of BCL-2 could not be totally excluded in these cells. These 
observations were almost entirely reproducible in the other three resistant models (Supplemental Fig. 
5), supporting the notion that BCL-XL and/or MCL-1 significantly contributed to the observed 
chemoresistance in the different resistance models.  
 
Modulation of glutamine uptake and/or metabolism enhances sensitivity to BH3 mimetics 
 Although the above results demonstrate that a combination of BH3 mimetics can overcome 
the resistance, such an approach targeting multiple members of the BCL-2 family requires careful 
evaluation of the therapeutic index, as these proteins perform redundant functions in the maintenance 
of normal cellular homeostasis. An alternative strategy to overcome chemoresistance to BH3 
mimetics could be achieved by altered metabolism, as depriving cells of glutamine has recently been 
shown to overcome MCL-1-mediated chemoresistance in multiple myeloma.19 In our experiments, 
glutamine deprivation for 16 h alone did not exhibit any effect on overall cell survival and yet, 
sensitised both the sensitive (A) and resistant (E) cells to BH3 mimetic-mediated apoptosis (Fig. 2A). 
The increase in apoptosis observed in both sensitive (A) and resistant (E) cells indicates that 
glutamine deprivation most likely provides an additional cytotoxic cue that induces apoptosis in the 
sensitive and resistant cells, but could also bypass the resistance mechanism in the resistant cells. 
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Nevertheless, our results suggest that targeting the glutamine metabolic pathway could enhance 
apoptosis and circumvent chemoresistance to BH3 mimetics in all our resistance models (Fig. 2A and 
Supplemental Fig. 6). To investigate the therapeutic potential of this approach, we wished to further 
understand how changes in glutamine metabolism might alter BH3 mimetic-mediated apoptosis.  
Glutamine is transported into cells primarily via the SLC1A5 transporter and metabolised to 
glutamate, primarily via glutaminase (GLS)-mediated glutaminolysis.22 Alternatively, glutamate can 
be generated from glutamine as a by-product of the hexosamine biosynthetic pathway, during the 
conversion of fructose-6-phosphate to glucosamine-6-phosphate, catalysed by the enzyme, 
glutamine:fructose-6-phosphate-amidotransferase (GFAT) (Fig. 2B).22 Glutamate can then generate α-
ketoglutarate (α-KG) either via glutamate dehydrogenase (GLUD)-mediated oxidative deamination or 
a series of aminotransferase reactions (Fig. 2B).14,22 Downregulation by RNA interference or 
pharmacological inhibition of key players involved in both glutamine uptake and its subsequent 
metabolism restored sensitivity of chemoresistant K562 cells to A-1331852-mediated apoptosis, albeit 
to varying degrees (Figs. 2C and D). While downregulation of SLC1A5 and GLS resulted in enhanced 
sensitivity to A-1331852-mediated apoptosis in the different cell lines tested, inhibition of other 
enzymes in the glutamine metabolic pathway produced more modest effects (Figs. 2C, D and 
Supplemental Fig. 7). 
 
Targeting reductive carboxylation enhances sensitivity to BH3 mimetics 
 Metabolic supplementation of the glutamine-deprived cells with either glutamine or a-KG 
restored the resistance of K562 cells to A1331852-induced apoptosis (Fig. 3A). Since glutamine-
derived a-KG feeds into the tricarboxylic acid (TCA) cycle, we wished to explore the functions of the 
TCA cycle and its intermediates in chemoresistance to BH3 mimetics. For this, we supplemented 
glutamine-deprived cells with TCA intermediates, such as oxaloacetate and citrate. Strikingly, 
supplementation with citrate, but not oxaloacetate, restored the resistance of K562 cells to A1331852-
induced apoptosis (Fig. 3A). These results suggested that conversion of a-KG to citrate via reductive 
carboxylation may play a role in regulating sensitivity to BH3 mimetics.  
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Reductive carboxylation involves the conversion of a-KG to isocitrate (catalysed by isocitrate 
dehydrogenases 1 and 2; IDH1/2), which then generates citrate (catalysed by aconitase) (Fig. 3B).23 
While IDH1/2 catalyse reductive carboxylation of α-KG, another isoform of isocitrate dehydrogenase, 
IDH3 catalyses the reverse-conversion of isocitrate to a-KG.23 Silencing the expression of IDH2 and 
aconitase, but not IDH3, restored the sensitivity of chemoresistant K562 cells to A-1331852-mediated 
apoptosis (Figs. 3C and D), suggesting that the availability of citrate could be associated with the 
chemoresistance phenotype. To test this, IDH2-downregulated K562 cells were supplemented with 
citrate to identify whether addition of citrate could overcome the inhibition of reductive carboxylation 
and revert the associated increase in A-1331852-induced apoptosis. Indeed, cells supplemented with 
citrate, but not glutamine or a-KG, restored the chemoresistance of IDH2 downregulated cells (Fig. 
3E), thus confirming the involvement of reductive carboxylation and the availability of citrate as 
crucial players for the observed chemoresistance.  
 
Downregulation of lipogenesis and cholesterogenesis enhances sensitivity to BH3 mimetics 
 Since citrate generated as a consequence of reductive carboxylation of a-KG is a major 
source of carbon for lipid synthesis, we wished to investigate whether inhibition of lipogenesis could 
enhance sensitivity to BH3 mimetics (Fig. 4A). Using a complementary approach of genetic and 
pharmacological inhibition of ATP-citrate lyase (ACLY), which catalyses the conversion of citrate to 
acetyl-CoA,24,25 as well as Fatty acid synthase (FASN), which synthesises long chain fatty acids 
following the condensation of acetyl-CoA and malonyl-CoA,26,27 we identified that modulation of 
lipogenesis pathway, either using genetic silencing or pharmacological inhibition of ACLY (using 
SB204990) or FASN (using GSK2194069) could enhance sensitivity of cells to BH3 mimetics (Fig. 
4B, C and Supplemental Figs. 7C and D). Furthermore, metabolic supplementation with palmitate (the 
product of FASN; Fig. 4A) in cells treated with GSK2194069 reverted the sensitised cells to their 
original chemoresistant phenotype (Fig. 4D), thus obviating a requirement for FASN. These findings 
conclusively demonstrated that enhanced lipogenesis was associated with chemoresistance to BH3 
12 
 
mimetics and targeting lipogenesis could circumvent such resistance by enhancing BH3 mimetic-
mediated apoptosis. 
 Acetyl-CoA generated from citrate can also feed into the cholesterol biosynthetic pathway, 
thus resulting in enhanced cholesterol production in cells. Targeting the rate-limiting step of 
cholesterol biosynthesis (catalysed by HMG-CoA reductase; HMGR), either by genetic knockdowns 
(Fig. 4E) or pharmacological inhibition, using three widely used statins, simvastatin, atorvastatin and 
pitavastatin (Fig. 4F) reversed resistance and restored the sensitivity of cells to BH3 mimetics (Figs. 
4E, F and Supplemental Fig. 7E). Taken together, these data demonstrate that inhibition of several key 
players in lipid synthesis, including ACLY, FASN and HMGR, enhance the sensitivity to BH3 
mimetics.  
 
Targeting the mTOR signalling cascade enhances sensitivity to BH3 mimetics 
 Since glutamine metabolism has been extensively implicated in mTOR signalling,22,28 we 
speculated whether targeting mTOR kinases could enhance sensitivity to BH3 mimetics. Inhibition of 
mTOR kinases with rapamycin and torin-1 resulted in significant sensitisation of cells to BH3 
mediated apoptosis (Fig. 5A and Supplemental Fig. 7F). To identify whether torin-1-mediated 
sensitisation of cells to apoptosis was due to autophagy, we exposed the sensitive and resistant cells to 
bafilomycin A1 (Baf A1), which blocks the autophagic flux by preventing lysosomal fusion of the 
autophagosomes. Exposure to bafilomycin A1 failed to revert torin-1-mediated chemosensitisation, 
suggesting that this effect could be independent of autophagy (Fig. 5B). Furthermore, genetic 
silencing of autophagy proteins, ATG5 and ATG7, which are critical for autophagy induction, also 
failed to revert torin-1-mediated sensitisation (Fig. 5C), confirming our finding that mTOR inhibition 
circumvented resistance and enhanced sensitivity to BH3 mimetics independent of autophagy. In 
summary, our findings demonstrate that modulation of glutamine metabolism and its downstream 
signalling pathways, namely reductive carboxylation, lipogenesis and cholesterogenesis, as well as 
inhibition of mTOR signalling could enhance the therapeutic efficacy of BH3 mimetic therapy 
thereby circumventing chemoresistance to BH3 mimetics (Fig. 5D).  
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Targeting intermediary metabolism enhances sensitivity to navitoclax in primary CLL patient 
samples 
 Our results indicate that targeting different facets of intermediary metabolism enhanced 
sensitivity to different BH3 mimetics in cell lines derived from relevant haematological malignancies. 
To further extend our observations in cell lines to primary patient samples, we used CLL cells isolated 
from patients during the lead-in period (L1D1) as well as cells from the same patients after 5 cycles of 
navitoclax therapy (C5D1), as previously detailed in Figure 1. Using these samples, we wished to 
assess whether modulating glutamine metabolism would enhance apoptosis mediated by navitoclax. 
For this, we exposed CLL cells to CB-839 and Simvastatin for 24 h followed by navitoclax for 4 h 
and assessed the extent of apoptosis. In agreement with our cell line data, both CB-839 and statins 
overcame the resistance to navitoclax-mediated apoptosis in primary CLL cells (Figure 6), supporting 
the therapeutic translatability of our data from cell lines to patients. 
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Discussion 
  Anti-apoptotic BCL-2 family members have been attractive drug targets both because of their 
high expression levels in several cancers and also their well-characterised pro-survival roles. Even 
with extensive supportive in vitro data, the use of BH3 mimetics in treating cancer patients is still in 
its infancy, with venetoclax, a BCL-2 specific inhibitor, only recently receiving approval for treatment 
of refractory chronic lymphocytic leukaemia.4 The development of BH3 mimetics to target BCL-XL 
and MCL-1 in patients will be extremely valuable in the treatment of several cancer types. However 
potential mechanisms of resistance to BH3 mimetics need to be recognised as they emerge and ways 
to circumvent resistance identified. Several resistance mechanisms, including mutations of the target 
site,29 post-translational modifications,30,31 and elevated levels of anti-apoptotic BCL-2 family 
members,8,11,32,33 have already been identified. While some of these resistance mechanisms could be 
overcome by co-administration of other specific BH3 mimetics that target BCL-XL and/or MCL-1,5-7 
such inhibitors are not yet clinically available and the potential toxicities associated with the 
simultaneous inhibition of multiple BCL-2 family members are not known.  
 Measures to overcome chemoresistance have resulted in exploring the therapeutic benefits of 
modulating intermediary metabolism in BH3 mimetic-mediated apoptosis.19,20,34 Although the 
mechanisms by which glutamine could regulate cancer cell proliferation have been extensively 
studied, the interrelationship between glutamine metabolism and apoptosis requires further study. 
Previous findings have reported a dependence on Myc for glutamine-mediated apoptosis14 and that c-
Myc activates glutaminolysis by upregulating both the glutamine transporter, SLC1A5, and 
glutaminase, GLS-1.35,36 However, we were unable to detect an increase in expression levels of Myc, 
SLC1A5 or GLS-1 in our resistance models (Fig. 3 and data not shown). The ability of glutamine to 
regulate apoptosis and/or chemoresistance could also be due to its regulatory effect on mitochondrial 
oxidative phosphorylation.20 Although we do not entirely understand how glutamine metabolism 
impinges on apoptosis at this point, our data strongly support the notion that modulating glutamine 
metabolism and its related signalling pathways, such as reductive carboxylation, lipogenesis, 
cholesterogenesis and mTOR signalling could enhance BH3 mimetic-mediated apoptosis in several 
haematological malignancies (Figs. 3-6). This is particularly promising, as glutaminase inhibitors, 
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such as CB-839 and related drugs are already in clinical trials for the treatment of several 
malignancies20,37 and other drugs targeting cholesterogenesis, such as statins are the most commonly 
prescribed drugs to millions of people worldwide. While this manuscript was in preparation, an 
independent study comparing a large cohort of CLL patients, many of whom were statin users, 
reported that response to venetoclax/ ABT-199 was enhanced among statin users in three different 
clinical trials.44 These findings highlight the possibility of repurposing several drugs targeting the 
intermediary metabolic pathways in conjunction with BH3 mimetic therapy to enhance the therapeutic 
effectiveness and overcome the emerging chemoresistance in several cancers.   
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Figure Legends  
 
Figure 1.  Haematological malignancies acquire rapid resistance to BH3 mimetics. (A) Blood 
samples collected from CLL patients (n=5), either prior to the first in vivo dose of navitoclax or 4 h 
after dosing during different stages of treatment - day 1 of the initial lead-in-period (L1D1), day 1 of 
cycle 1 (C1D1), day 1 of cycle 3 (C3D1) or day 1 of  cycle 5 (C5D1) - were incubated ex vivo and the 
extent of apoptosis in the CD19+ CLL cells assessed at the indicated time points by 
phosphatidylserine (PS) externalisation. (B) CLL cells isolated from these patients at the beginning of 
each treatment cycle, as indicated in the figure, were exposed in vitro to increasing concentrations of 
ABT-263, the extent of apoptosis assessed and IC50 values are shown. (C) Scheme for establishing 
resistance to specific BH3 mimetics in relevant haematological cell lines, as explained in the methods. 
Sensitive (A) and resistant (E) cells of MAVER-1, K562 and H929 cells were exposed for 4 h to 
ABT-199 (10 nM), A-1331852 (10 nM) and A-1210477 (5 µM), respectively, and apoptosis assessed. 
(D-F) Combination with some but not all BH3 mimetics restores the apoptotic sensitivity of resistant 
(E) MAVER-1, K562 and H929 cells exposed for 4 h to ABT-199 (10 nM), A-1331852 (10 nM) or 
A-1210477 (5 µM), respectively. ***P ⩽0.001, **P⩽0.01; Error bars = Mean ± SEM (n=3). 
 
Figure 2. Inhibition of glutamine uptake and metabolism enhances sensitivity to BH3 mimetics. 
(A) Deprivation of glutamine (Gln) for 16 h restores the apoptotic sensitivity of resistant (E) 
MAVER-1, K562 and H929 cells to a 4 h exposure of the indicated BH3 mimetic. (B) Scheme 
representing the glutamine uptake and metabolism pathway. (C) Apoptotic sensitivity of K562 
resistant (E) cells exposed to A-1331852 (10 nM) for 4 h was restored following genetic knockdown 
for 72 h with the indicated siRNA. (D)  Apoptotic sensitivity of K562 resistant (E) cells exposed to A-
1331852 (10 nM) for 4 h was restored following pharmacological inhibition of glutamine uptake or 
metabolism with GPNA (5 mM) for 48 h, CB-839 (10 µM) for 72 h, azaserine (25 µM) for 16 h and 
AOA (500 µM) for 24 h but not with EGCG (50 µM) for 24 h. Western blots confirmed the 
knockdown efficiency of the different siRNAs. ***P ⩽0.001, **P⩽0.01; Error bars = Mean ± SEM 
(n=3). 
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Figure 3. Modulation of reductive carboxylation enhances sensitivity to BH3 mimetics. (A) K562 
(A and E) cells were cultured in normal RPMI medium or glutamine-free medium with and without 
the supplementation of glutamine (2 mM), exposed to A-1331852 (10 nM) for 4 h and the extent of 
apoptosis assessed. Addition of citrate (4 mM) and a-ketoglutarate (a-KG) (4 mM) but not 
oxaloacetate (4 mM) for 16 h reversed the sensitivity of the resistant (E) cells in glutamine-deprived 
media. (B) Scheme representing the link between tricarboxylic acid (TCA) cycle and reductive 
carboxylation.  (C) K562 (A and E) cells were transfected with siRNAs against IDH2, IDH3 and 
aconitase for 72 h, followed by a 4 h exposure to A-1331852 and apoptosis assessed. (D) Western 
blots confirmed the knockdown efficiency of the different siRNAs. (E) K562 (A and E) cells, 
transfected with a siRNA against IDH2 for 72 h, were glutamine deprived with and without the 
supplementation of glutamine (2 mM), a-ketoglutarate (a-KG) or citrate (both at 4 mM) for 16 h and 
the extent of apoptosis following A-1331852 (10 nM) for 4 h was assessed. ***P ⩽0.001. Error bars 
= Mean ± SEM (n=3). 
 
Figure 4. Inhibition of lipogenesis and cholesterogenesis enhances sensitivity to BH3 mimetics. 
(A) Scheme representing reductive carboxylation, lipogenesis and cholesterogenesis. (B) Apoptotic 
sensitivity of K562 resistant (E) cells exposed to A-1331852 (10 nM) for 4 h was restored following 
genetic knockdown for 72 h of key enzymes in fatty acid synthesis. Western blots confirmed the 
knockdown efficiency of the different siRNAs. (C) Apoptotic sensitivity of K562 resistant (E) cells 
exposed to A-1331852 (10 nM) for 4 h was restored following pharmacological inhibition of key 
enzymes in fatty acid synthesis using SB204990 (1 µM) for 72 h or GSK2194069 (100 nM) for 48 h. 
(D) Metabolic supplementation of K562 (A and E) cells with palmitate (50 µM) for 48 h prior to the 
exposure of cells to GSK2194069 (100 nM) overcame the sensitisation effect of GSK2194069 on A-
1331852-mediated apoptosis. (E) genetic knockdown for 72 h of HMGR or (F) pharmacological 
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inhibition of HMGR by simvastatin (250 nM) for 72 h, atorvastatin (10 µM) for 48 h or pitavastatin (1 
µM) for 72 h. ***P ⩽0.001; **P⩽0.01. Error bars = Mean ± SEM (n=3). 
 
Figure 5. Modulation of mTOR signalling enhances sensitivity to BH3 mimetics independent of 
autophagy. (A) Apoptotic sensitivity of K562 resistant (E) cells exposed to A-1331852 (10 nM) for 4 
h was restored following pharmacological inhibition of mTOR signalling using rapamycin (100 nM) 
or torin-1 (10 nM) for 16 h. (B) Inhibition of mTOR-regulated autophagy using 3-MA (10 mM) or 
bafilomycin A1 (100 nM) for 1 h, followed by torin-1 (10 nM) for a further 16 h, resulted in varying 
effects on A-1331852-mediated apoptosis. (C) Genetic knockdown of ATG5 and ATG7 for 72 h 
failed to revert torin-1 (10 nM)-mediated sensitisation of apoptosis in K562 resistant (E) cells, 
following A-1331852 (10 nM) for 4 h. Western blots confirmed the knockdown efficiency of ATG5 
and ATG7 siRNA. ***P ⩽0.001. Error bars = Mean ± SEM (n=3). (D) Scheme representing 
glutamine uptake by SLC1A5 (inhibited by GPNA), glutaminolysis (inhibited by CB-839) to generate 
a-ketoglutarate, reductive carboxylation of a-ketoglutarate to generate citrate, which produces acetyl-
CoA by a reaction catalysed by ACLY (inhibited by SB204990), which eventually results in 
lipogenesis (inhibited by GSK2194069) and cholesterogenesis (inhibited by statins). Glutamine 
uptake, metabolism and its downstream signalling cascade can feed into mTOR signalling (inhibited 
by torin-1), all of which promote cell growth. In this study, we demonstrate that modulation of these 
distinct intermediary metabolic pathways could successfully sensitise cancer cells to BH3 mimetic-
mediated apoptosis. 
 
Figure 6. Inhibition of GLS and HMGR circumvents resistance to navitoclax-mediated 
apoptosis in primary CLL cells. CLL cells isolated from 5 patients during the initial lead-in-period 
(L1D1) or day 1 of cycle 5 (C5D1) were cultured ex vivo on feeder layer for 24 h, followed by 
exposure for a further 24 h to (A) CB-839 (50 nM) or (B) simvastatin (10 nM), and removed from the 
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feeder layer for further exposure to navitoclax (50 nM) for 4 h. The extent of apoptosis was assessed 
as before. *P ⩽0.05. Error bars = Mean ± SEM (n=5). 
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Supplemental information  
 
Supplemental Figure S1. First in vivo dose of navitoclax resulted in marked ultrastructural 
changes in CLL cells. CLL cells isolated from two different patients prior to receiving navitoclax and 
4 h after the first in vivo dosing during day 1 of the lead-in-period (L1D1) were incubated ex vivo for a 
further 8 h, before fixation in 2% glutaraldehyde and transmission electron microscopy. CLL cells from 
patients exposed to navitoclax exhibited chromatin condensation and rupture of the outer mitochondrial 
membrane. Scale bar – 500 nm. 
Supplemental Figure S2. Rapid development of resistance to BH3 mimetic-mediated apoptosis in 
haematological cell lines. (A) Exposure of MAVER-1, K562 and H929 cells to ABT-199 (10 nM), A-
1331852 (10 nM) and A-1210477 (10 µM), respectively resulted in a time dependent induction of 
apoptosis as assessed by western blotting for the indicated proteins. (B-D) Schemes used for developing 
the other three models of drug resistance as described in the Methods. Assessment of apoptosis by PS 
externalisation showed that resistance developed in the different cellular models following exposure for 
4 h to ABT-199 (10 nM), A-1331852 (10 nM) and A-1210477 (5 µM), respectively. ***P ⩽0.001; 
Error bars = Mean ± SEM (n=3).  
Supplemental Figure S3. Resistance to BH3 mimetic-mediated apoptosis could not be attributed 
to marked changes in the expression levels of BCL2 family members. Immunoblots of BCL-2 
family members showed no major changes in the indicated cell lines, during the development of 
resistance, depicted as A, C and E. A is the sensitive parent line, whereas C and E are relatively more 
resistant to the BH3 mimetics compared to A. * in the PUMA immunoblot depicts a non-specific band. 
Supplemental Figure S4. Protein-protein interactions among anti- and pro-apoptotic BCL-2 
family proteins are similar in both sensitive and resistant cells. Immunoprecipitates of BIM and 
PUMA in MAVER-1, K562 and H929 (A and E) cells showed no major differences in the binding of 
the indicated proteins. BC represents the beads control.  
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Supplemental Figure S5. Resistance to BH3 mimetics in the different resistance models can be 
overcome by simultaneous inhibition of multiple BCL-2 members. (A-C) Sensitive and resistant 
lines of MAVER-1, K562 and H929 from the different resistance models, as explained in methods and 
depicted in Supplemental figure 2, were exposed for 4 h to ABT-199 (10 nM), A-1331852 (10 nM) or 
A-1210477 (5 µM) and the extent of apoptosis assessed by PS externalisation. ***P ⩽0.001, **P⩽0.01; 
Error bars = Mean ± SEM (n=3). 
Supplemental Figure S6. Glutamine deprivation sensitises the different cell lines to BH3 mimetic-
mediated apoptosis. (A-C) Sensitive and resistant lines of MAVER-1, K562 and H929 from the 
different resistance models, as explained in methods and depicted in Supplemental figure 2, were 
deprived of glutamine for 16 h and the extent of apoptosis assessed following a 4 h exposure to ABT-
199 (10 nM), A-1331852 (10 nM) or A-1210477 (5 µM). ***P ⩽0.001; Error bars = Mean ± SEM 
(n=3). 
Supplemental Figure S7. Modulation of intermediary metabolism enhances sensitivity to BH3 
mimetics in distinct haematological cell lines Exposure to GPNA (5 mM for 48 h), CB-839 (10 µM 
for 72 h), SB204990 (1 µM for 72 h), GSK2194069 (100 nM for 48 h), simvastatin (250 nM for 72 h) 
or torin-1 (10 nM for 24 h) enhances the sensitivity of the chemoresistant MAVER-1 and H929 cells to 
their respective BH3 mimetics. Apoptosis was assessed by PS externalisation following exposure for 4 
h to ABT-199 (10 nM) or A-1210477 (5 µM). ***P ⩽0.001; *P⩽0.1; Error bars = Mean ± SEM (n=3). 
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